A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Business We are a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by our deep commitment to improving the lives of people living with these conditions. We have built a robust commercial infrastructure to support the successful commercialization of ORLADEYO, an oral, once-daily therapy discovered and developed internally for the prevention of HAE attacks. Our business strategy includes leveraging this established commercial platform to successfully commercialize a pipeline of potential first-in-class or best-in class oral small molecule and injectable protein therapeutics targeting a range of rare diseases. These programs are being pursued through both internal discovery efforts and strategic business development.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 875M | 875M | 451M | 331M | 271M | 157M |
| Net Income | 264M | 264M | -89M | -227M | -247M | - |
| EPS | $1.21 | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1,030.00 |
| Free Cash Flow | 345M | 345M | -53M | -97M | -163M | -145M |
| ROIC | 65.4% | 67.0% | - | -20.1% | -27.0% | - |
| Gross Margin | 97.8% | 97.8% | 97.3% | 98.6% | 97.6% | 95.4% |
| Debt/Equity | 0.00 | -0.10 | -0.69 | -0.69 | -0.81 | -1.63 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 341M | 341M | - | -104M | -148M | -178M |
| Operating Margin | 39.0% | 39.0% | - | -31.3% | -54.8% | -113.1% |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 218M | 218M | 207M | 192M | 186M | 188M |
BIOCRYST PHARMACEUTICALS INC passes 2 of 9 quality checks, indicating weak fundamentals.
BIOCRYST PHARMACEUTICALS INC trades at 7.8x trailing earnings, compared to its 15-year median P/E of 6.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 6.8x vs a median of 4.8x. The company's 5-year average ROIC is 6.6% with a gross margin of 97.4%.
BIOCRYST PHARMACEUTICALS INC (BCRX) has a current P/E ratio of 7.8, compared to its historical median P/E of 6.3. The stock is currently considered Expensive based on its historical valuation range.
BIOCRYST PHARMACEUTICALS INC (BCRX) has a 5-year average return on invested capital (ROIC) of 6.6%. This is below average and may indicate limited pricing power.
BIOCRYST PHARMACEUTICALS INC (BCRX) has a market capitalization of $2.1B. It is classified as a mid-cap stock.
BIOCRYST PHARMACEUTICALS INC (BCRX) does not currently pay a regular dividend.
Based on historical P/E analysis, BIOCRYST PHARMACEUTICALS INC (BCRX) appears expensive. The current P/E of 7.8 is 23% above its historical median of 6.3.
BIOCRYST PHARMACEUTICALS INC (BCRX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported annual revenue of $875 million in its most recent fiscal year, based on SEC EDGAR filings.
BIOCRYST PHARMACEUTICALS INC (BCRX) has a net profit margin of 30.2%. This is a strong margin indicating high profitability.
BIOCRYST PHARMACEUTICALS INC (BCRX) generated $345 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
BIOCRYST PHARMACEUTICALS INC (BCRX) reported earnings per share (EPS) of $1.21 in its most recent fiscal year.
BIOCRYST PHARMACEUTICALS INC (BCRX) has a 5-year average gross margin of 97.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for BIOCRYST PHARMACEUTICALS INC (BCRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BIOCRYST PHARMACEUTICALS INC (BCRX) has a book value per share of $-0.55, based on its most recent annual SEC filing.